Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7552302 | 0.86 | ACLY (0.64) | ACLYAKR1C3AKR1C2KDM4ESMN1; SMN2 | |
| SCHEMBL7556102 | 0.79 | ACLY (0.62) | ACLYKDM4ESMN1; SMN2HSD17B10MCL1 | |
| SCHEMBL12115606 | 0.79 | HSD17B2 (0.56) | TDP1HSD17B10KMT2A | |
| SCHEMBL6307782 | 0.79 | KDM4E (0.62) | ACLYAKR1C3AKR1C2KDM4ESMN1; SMN2 | |
| SCHEMBL23141169 | 0.78 | KDM4E (0.49) | ACLYKDM4ESMN1; SMN2HSD17B10MCL1 | |
| SCHEMBL7552232 | 0.78 | LMNA (0.54) | ACLYAKR1C3AKR1C2KDM4ESMN1; SMN2 | |
| SCHEMBL2365878 | 0.78 | ALDH1A1 (0.58) | ACLYAKR1C3AKR1C2KDM4ESMN1; SMN2 | |
| SCHEMBL221906 | 0.78 | ACLY (0.49) | ACLYKDM4ESMN1; SMN2HSD17B10MCL1 | |
| SCHEMBL7556603 | 0.78 | CCR2 (0.63) | ACLYKDM4ESMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL28047975 | 0.77 | KDM4E (0.50) | ACLYKDM4ESMN1; SMN2HSD17B10MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196354-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180022701-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-01-25 | — | — | US | disclosed |
| US-9745265-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196354-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | RORB, RORA, RORC | ACLY 3512/4885TDP1 4512/4885AKR1C3 2024/4885 |
| US-20180022701-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORA, RORC | ACLY 3512/4885TDP1 4512/4885AKR1C3 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.